Fuzheng Huayu Tablets Against Posthepatitic Cirrhosis

Shanghai University of Traditional Chinese Medicine

Status and phase

Completed

Phase 4

Conditions

Posthepatitic Cirrhosis

Treatments

Drug: sham Fuzheng Huayu Tablets (placebo)

Drug: Fuzheng Huayu Tablets

Study type

Interventional

Funder types

Other

Identifiers

NCT00543426

06DZ19728

Details and patient eligibility

About

The primary purpose of the trial is adopted Fuzheng Huayu tablets against posthepatitic cirrhosis, and to build a standard evaluation system for efficacy of traditional Chinese medicine (TCM).

The second purpose is according to the international clinical guideline and the specialty of TCM to build a standard clinical trial regulation for traditional Chinese medicine.

Enrollment

200 patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Clinical diagnosis of B Post hepatitic cirrhosis.
Male or female patients between 18~65 years old.
Written informed consent.

Exclusion criteria

Child-Pugh C above 12, or ALT > 2×ULN, TBiL > 2×ULN, or combined with hepatic encephacopathy, Obstinate ascites, bleeding tendency, hepato-renal syndrome, or primary liver cancer.
Combined with severe heart, gallbladder, kidney, endocrine system, hemopoietic system or nervous system disease.
Deformed man by the law.
Pregnancy or breast feeding women, or unwilling to have contraception.
Irritability body constitution, or irritability of the Fuzheng Huayu Capsules.
Enter other trials lately one month.
Other cause of cirrhosis.